PhaseBio Pharmaceuticals (NASDAQ:PHAS – Get Free Report) and ImmunoPrecise Antibodies (NASDAQ:IPA – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, institutional ownership and earnings. Analyst Ratings This is a summary of […]
PhaseBio Pharmaceuticals (NASDAQ:PHAS – Get Free Report) and ImmunoPrecise Antibodies (NASDAQ:IPA – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership. Insider & Institutional Ownership 49.0% of PhaseBio […]
PhaseBio Pharmaceuticals (NASDAQ:PHAS – Get Free Report) and ImmunoPrecise Antibodies (NASDAQ:IPA – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership. Analyst Ratings This is a breakdown of […]
ImmunoPrecise Antibodies (NASDAQ:IPA – Get Free Report) is set to post its quarterly earnings results before the market opens on Thursday, March 14th. Analysts expect ImmunoPrecise Antibodies to post earnings of ($0.08) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link. ImmunoPrecise Antibodies […]
Ingalls & Snyder LLC decreased its position in ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA – Free Report) by 3.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,028,253 shares of the company’s stock after selling 31,802 shares during the quarter. Ingalls & […]